Atara Biotherapeutics, Inc. announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the FDA of the Biologics License Application (BLA) resubmission for tabelecleucel, with… read more.
United Therapeutics Corporation announced that the FDA has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure… read more.
Pre-retrieval imaging is moving liver transplantation toward a more precise and less invasive era. A new evidence synthesis shows how ultrasound, computed tomography, and magnetic resonance imaging can… read more.
Nearly half of Americans with kidney failure who are referred for transplantation never begin the process required to be considered for a new organ, a new study shows,… read more.
Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to… read more.
A reduced-intensity bone marrow transplant regimen developed by Johns Hopkins physicians provides durable engraftment with low rejection rates and also may preserve fertility, according to results of a… read more.
Speaking today at the 46th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) Jagbir Gill, MD, Associate Professor of Medicine in the Division… read more.
The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years… read more.
UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a… read more.
Hansa Biopharma AB announced that the FDA has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User… read more.
Hansa Biopharma AB announced that its Biologics License Application (BLA) for imlifidase has been accepted by the FDA. The FDA’s filing review was completed on day 60 which… read more.
Texas Children’s once again continues to lead the nation in performing the most pediatric transplants, as reported by the Organ Procurement & Transplantation Network (OPTN), the country’s unique public-private… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
